Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vitamin K–dependent clotting factors (prothrombin [FII], factor VII, factor IX, factor X) are serine proteases essential for the propagation of the coagulation cascade. Their activity depends on post-translational gamma-carboxylation, a process that requires vitamin K, allowing these proteins to bind membranes and calcium, enabling proteolytic activation steps in clot formation. Therapeutic provision of these factors, via plasma-derived concentrates or recombinant proteins, is a mainstay for correcting deficiencies due to inherited or acquired disorders, or for reversal of vitamin K antagonist therapy[1][2][4][5].
Replacement or supplementation of deficient clotting factor(s) to restore hemostasis Promotion of coagulation cascade via enzymatic cleavage of pro-enzymes to active forms (serine protease activity)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitamin K-dependent clotting factor (specifically, Factor II [Prothrombin], Factor VII [often used as activated FVIIa], Factor IX, Factor X) (None).